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Abstract 
Objectives:  Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. 
Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in 
RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive 
protein is also a major risk factor. However, the contribution of traditional cardiovascular 
risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in 
psoriatic arthritis (PsA) and RA. We examine the incidence of Major Adverse Cardiac Events 
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(MACE) among patients with RA, PsA, psoriasis and controls adjusting for risk factors, 
inflammation and Disease Modifying Anti-Rheumatic Drug treatment, to better define 
cardiovascular risk. 
Methods: Using the Secure Anonymised Information Linkage databank, comprising routinely 
collected Welsh health data from 1999 to 2013, the incidence and first occurrence of a 
MACE in individuals with RA (n=8650), PsA (n=2128) and psoriasis (n=24630) compared to 
controls (n=1187706) was investigated. 
Results:  Traditional cardiovascular risk factors are higher in RA, PsA and psoriasis than 
controls. After adjusting for these factors, additional cardiovascular risk was only 
significantly increased in female RA patients (HR: 1.3, 95% CI: 1.0-1.7, p=0.047) and psoriasis 
(HR: 1.2, 95% CI: 1.0-1.4, p=0.022) but not statistically significant for PsA (HR: 1.5, 95% CI: 
0.9-2.5, p=0.126). ESR and CRP were increased in patients with RA but not in patients with 
psoriasis.  
Conclusion:  Additional increased cardiovascular risk was observed in female RA and 
psoriasis but not PsA. Systematic inflammation is higher in RA but not psoriasis, indicating 
that there are varying mediators of cardiovascular risk across these conditions.  
Introduction  
Patients with inflammatory arthritis such as rheumatoid Arthritis (RA), have a higher 
incidence of cardiovascular events.(1, 2) Importantly, cardiovascular risk in RA cannot be 
explained by traditional cardiovascular risk factors alone (3) and systemic inflammation is  
independently associated with increased cardiovascular risk.(4) Consequently, 
cardiovascular risk scores used routinely in the general population, such as the Framingham 
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risk score underestimate risk in patients with RA.(5) The QRISK2 score includes RA as an 
independent risk factor and inflates 10-year cardiovascular risk estimates for those with RA 
by 1.38 times in males and 1.5 times in females. This is comparable to those recommended 
by European League Against Rheumatism (EULAR) in patients with RA, which recommends a 
multiplication factor of 1.5 to the algorithms calculating cardiovascular risk factor for the 
general population.(6)  In RA, systematic review and meta-analysis suggested treatment 
with tumour necrosis factor inhibitors and methotrexate could reduce cardiovascular 
events, however, data on the effect of DMARDs and biologic treatment on cardiovascular 
risk in psoriasis and Psoriatic Arthritis (PsA) were limited.(7) PsA is another common chronic 
inflammatory arthritis occurring in a third of patients with psoriasis. A meta-analysis 
concluded that ischemic heart disease, peripheral vascular disease and atherosclerosis are 
increased in patients with psoriasis and traditional cardiovascular risk factors such as 
diabetes, hypertension, dyslipidaemia, high body mass index, and metabolic syndrome were 
also more common in these patients.(8) (9, 10) Moreover, comorbidities were associated 
with more severe psoriasis.  
Whether increased cardiovascular risk in psoriasis and PsA is due to more prevalent 
traditional cardiovascular risk factors remains unclear. Studies demonstrating an increased 
risk of cardiovascular disease, when controlling for traditional cardiovascular risk factors 
have tended to be retrospective, population-based studies  (11, 12) (13) (14). Limitations of 
these studies include missing data on family history of ischaemic heart disease, use of 
NSAIDs and systemic inflammation. Furthermore, case-control approaches frequently 
adopted by such studies may not be as strong as cohort studies.  
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A systematic review of cardiovascular comorbidities in PsA reviewed 28 eligible studies.(15) 
Data from these studies were conflicting with only one study reporting increased 
cardiovascular mortality. Four studies (4810 PsA patients in total) found increased 
cardiovascular comorbidity, however, only one of these was a prospective study with 453 
patients.(16)  
A meta-analysis was carried out by Alamanos et al. and found a wide variation in the annual 
incidence of PsA, ranging from 0.1 to 23.1 cases per 100,000 (median 6.4/100,000) 
inhabitants with large differences between countries. The mean age at diagnosis varied 
between 40.7 and 52 years (median 47.7 years). Prevalence rates also varied between 1 
case per 100,000 (Japan) to 420 per 100,000 (Italy) inhabitants.(17) Depending on the 
definitions used (e.g. diagnostic codes, patient self-reporting, rheumatologist diagnosis and 
classification criteria) prevalence and incidence rates of PsA in psoriasis patients range from 
6% to 41%.  
More recently, a systematic review and meta-analysis found PsA to be an independent risk 
factor for cardiovascular disease. However, this study did not take into account traditional 
cardiovascular risk factors.(18)  Other studies using surrogate markers, such as flow-
mediated occlusion and carotid intima-media thickness, found increased prevalence of 
atherosclerosis. However, many studies have also found that traditional cardiovascular risk 
factors: hypertension, diabetes and dyslipidaemia were also more common in patients with 
PsA.(19-22) A single-centre study, based on hospital data, found cardiovascular 
comorbidities and traditional cardiovascular risk factors were more common in PsA 
compared to psoriasis patients.(23) In a prospective cohort study of 158 PsA patients 
followed-up from time of diagnosis, the 10-year cumulative cardiovascular events increased 
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by 17%.(24) Similar to RA, Framingham risk score significantly underestimated risk in these 
patients.  
Two inception cohorts using the Clinical Practice Research Datalink have provided opposing 
results; Parisi et al(25)., found no increased risk of major cardiovascular events while Degran 
et al(26)., reported an increased risk for severe psoriasis patients.  
Recently, a large prospective, UK-based study on data from The Health Improvement 
Network dataset found that cardiovascular events by 40-50% in patients with RA and severe 
psoriasis (severity defined by DMARD usage).(27) In patients with PsA, cardiovascular risk 
increased by 20%, which was significantly lower than patients with RA or severe psoriasis. In 
contrast to patients with psoriasis taking DMARDs, patients with PsA taking DMARDs have 
lower risk of cardiovascular events. However, it is not clear if this suggests an effect of 
DMARDs on cardiovascular risk or on disease severity. Similar to previous studies, family 
history of cardiovascular diseases was not available. In addition, data on ESR or CRP were 
not available, so the impact of systemic inflammation and DMARDs could not be 
assessed.(2) Recently, a German study investigating RA has demonstrated that ESR and CRP 
are significantly elevated in the 6 months prior to an MI compared to controls. There was 
also a strong association between higher CRP and MI. Furthermore, treatment with 
prednisone, biologic or other DMARDs was not associated with risk of MI. (28)  
Here we examine the cardiovascular events in patients with RA, PsA and psoriasis using the 
Secure Anonymised Information Linked (SAIL) Databank in Wales, which includes nation-
wide health data from primary and secondary care, including family history of 
cardiovascular disease and ESR as linking health data provides a more robust, multi-source 
perspective which enhances analysis compared to using isolated datasets. (29)  
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Methods 
Study design and patients 
The SAIL databank,(30) is a data repository which allows person-based data linkage across 
datasets. This databank includes Welsh GP data, hospital in- and out-patient records, as well 
as mortality data collected by the Office of National Statistics (ONS). SAIL holds over a billion 
anonymised records. It uses a split-file approach to ensure anonymisation and overcome 
issues of confidentiality and disclosure in health-related data warehousing. Demographic 
data is sent to a partner organization, NHS Wales Informatics Service, where identifiable 
information is removed; clinical data are sent directly to the SAIL Databank and an individual 
is assigned an encrypted Anonymised Linking Field (ALF). The ALF is used to link anonymised 
individuals across datasets, facilitating longitudinal analysis of an individual's journey 
through multiple health, education and social datasets.(31) Data collected by GPs is 
captured via Read Codes (5-digit codes related to diagnosis, medication and process of care 
codes).(32) Hospital inpatient and outpatient data are collected in the Patient Episode 
Database for Wales, which contains clinical information regarding patients’ hospital 
admissions, discharges, diagnoses and operations, using the International Classification of 
Diseases (ICD-10) clinical coding system. The ONS Mortality dataset contains demographic 
data, place of death and underlying cause of death (also ICD-10).  
Patients were identified from GP records from the SAIL databank.  Individuals who had at 
least one READ Code consistent with RA, PsA or psoriasis (Supplementary Table 1) in their 
GP records were assigned to their respective condition groups. Only those who were over 
the age of 18 at first mention, which was considered as the diagnosis date, were included. 
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Data was linked at the person-level to hospital admissions, and ONS mortality data to 
explore cardiovascular events.  
The PsA group comprised individuals positive for PsA codes within their GP record but could 
additionally have psoriasis codes in their medical history. The psoriasis group had codes for 
psoriasis only. The RA group may present with a skin disorder initially and so individuals who 
had RA codes were assigned to the RA group (whether or not they also had psoriasis and 
PsA codes present). The control population comprised of individuals who did not present 
with RA, PsA or psoriasis codes. A random date was generated for the control population 
that could be used as a substitute for a ‘diagnosis date.’  Data was included from January 
1999 to December 2013 for optimum data coverage purposes.  
Ethical approval 
Data held in the SAIL databank are anonymised and therefore, no ethical approval is 
required. All data contained in SAIL has the permission from the relevant Caldicott Guardian 
or Data Protection Officer. SAIL-related projects are required to obtain Information 
Governance Review Panel (IGRP) approval. 
Major adverse cardiac events (MACEs) 
Primary outcome measures were MACEs, namely, myocardial infarction (MI),  
cerebrovascular accident (CVA) and associated deaths identified from the GP, hospital 
admissions and ONS datasets (Supplementary Table 2 & 3 for coding definitions). 
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Covariates of interest and confounding factors 
Traditional cardiovascular risk factors included age at diagnosis, age at study start, gender, 
BMI, smoking status, hypertension, hyperlipidaemia, diabetes, previous cardiovascular 
disease and family history of cardiovascular disease were collected from the GP records 
where relevant READ Codes were present or calculated from available data (e.g. height and 
weight for BMI). Measure of inflammation was based on ESR. Potential confounders, such as 
medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), DMARDs, oral 
corticosteroids, and topical steroids) statistical analyses. All covariates and confounders 
were identified from the GP records and the codes used are available in Supplementary 
Tables 4 - 15.     
 
Statistical analysis 
Descriptive statistics were used to examine age, sex and covariate distribution for RA, PsA, 
psoriasis and the control population. A Cox proportional model was employed to calculate 
hazard ratios for each group. Censoring occurred when a patient died, lost to follow-up 
(moving out of Wales, so that health records were incomplete) or reaching the end of the 
study. 
Univariate analyses were performed to determine significance and candidate variables to be 
included in the Cox proportional hazard model. Significant covariates (p-value of 0.25 or 
less) were incorporated into the model (Supplementary Tables 16, 17 & 18).  
A subgroup analysis was performed which involved individuals who had no MACE events 
prior to diagnosis of RA, PsA or psoriasis.  
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Likelihood ratio tests were used to determine the significance of interactions. Missing data 
was treated as missing. 
Results 
The population consisted of 8,650 RA, 2,128 PsA and 24,630 psoriasis patients identified 
from GP records. The control population comprised 1,187,706 individuals present in the GP 
without codes for RA, PsA, or psoriasis.  The mean age of the study population was 
approximately 50 years. The characteristics of patients and the control group at baseline are 
reported in Table 1.  
The prevalence of co-morbidities and medications taken by the group are presented in 
Table 2. Individuals with RA tended to take more medication, with 68.2% and 54.3% having 
ever taken DMARDs and oral steroids, respectively. Hypertension, diabetes and 
hyperlipidaemia tended to be more prevalent in the RA, PsA and psoriasis patients. At the 
time of diagnosis, smoking was more prevalent in patients with RA and psoriasis but a 
similar rate of smoking was observed among patients with PsA and the control population. 
Interestingly, individuals who ever smoked were lower in patients with PsA than control, RA 
or psoriasis. Previous ischemic heart disease was more prevalent in RA and psoriasis but 
lower in patients with PsA. Family history of ischemic heart disease is more common in RA, 
psoriasis and PsA and use of NSAIDs, DMARDs and steroids were also higher in these 
patients compared to controls.  
In the control population, the incidence rate of MI was 1.9 per 1000 person-years follow-up 
and 3.0 per 1000 person-years for stroke. Incidence rates of MI, Stroke, and MACE were 
higher in patients with RA and psoriasis but not in PsA (Table 3).  
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After controlling for the traditional cardiovascular risk factors MACEs were statistically 
significantly increased for individuals with psoriasis (HR: 1.2, 95% CI: 1.0-1.4, p=0.022) but 
there was no evidence of an increase for RA and PsA patients  (Table 4) when compared to 
controls. However, when incorporating gender interactions by condition, RA was associated 
with increased MACEs in females (HR: 1.3, 95% CI: 1.0 to 1.7, p=0.047).  The greatest 
predictor of MACE was a previous MACE event (Supplementary Table 19 & 20).  
Subgroup analysis, which removed individuals who had MACE events prior to diagnosis, 
demonstrated that RA (HR: 1.2, 95% CI: 1.0-1.3, p=0.038) and psoriasis patients (HR: 1.1, 
95% CI: 1.0-1.3, p=0.025) had an increased risk of MACE in comparison to controls 
(Supplementary Table 21) but not for patients with PsA compared to controls. Furthermore, 
MACE remained significantly increased in patients with RA and psoriasis after the addition 
of NSAIDs, DMARDs, topical steroids and oral steroids into the statistical model. Likelihood 
odds ratio tests found no statistical significant interaction between DMARDs and MACEs by 
condition, meaning that DMARDs did not have significantly different effects within 
individuals with RA, PsA or psoriasis compared to controls (data not shown). When 
controlling for age, gender, and BMI there was a significant increase in the mean level of 
ESR in individuals with RA (regression coefficient: 4.9, 95% CI: 2.7 to 7.0, p=<0.001) but not 
psoriasis or psoriatic arthritis compared to controls.  
Sensitivity analysis included all individuals aged 50 years or below which demonstrated no 
increased risk of MACE for individuals with RA and PsA, however, the risk of MACE was 
significantly increased for individuals with psoriasis (HR: 1.3, 95% CI: 1.1 to 1.6, p= 0.015).  
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Discussion 
To our knowledge, this is the first study to demonstrate that patients with psoriasis, similar 
to patients with RA, have increased MACEs even after controlling for traditional 
cardiovascular risk factors including family history of ischaemic heart disease. This suggests 
additional factors contribute to the development of cardiovascular events in these 
conditions. MACEs were highest in patients with RA and these patients also had higher 
levels of inflammation, as indicated by increased ESR. In PsA, ESR levels were not 
significantly increased which may be explained in part by the individuals with RA being a 
more homogenous group of older females. Indeed, research has shown that elevated ESR is 
a significant predictor of cardiovascular risk in women with PsA (33) and so suggests a 
gender effect. Furthermore, psoriatic arthritis is a heterogeneous disease with differential 
effects on inflammatory markers; one of the limitations of the study is lack of data on the 
type of PsA which may explain the lack of statistical significant difference in ESR between 
PsA and controls. However, our findings replicate those reported by Paramarta el al, who 
demonstrated that ESR and CRP were normal in a PsA cohort (34). In RA, inflammation 
levels may explain the higher MACE events. However, inflammation was not higher for 
those with psoriasis when compared with controls and so may not explain the higher levels 
of MACE in the psoriasis population.  These findings are consistent with previous data in RA 
but are novel for psoriasis.  
Our data showed that MACE was not higher in those with PsA after controlling for 
traditional cardiovascular risk factors.  Previous findings from cross-sectional studies,(9, 10, 
35) and more recently, two population-based longitudinal studies have found increased 
12 
 
cardiovascular events in patients with PsA. One population study using data from the UK 
reported a 20% increased risk of MACEs in PsA although this study did not include family 
history of ischaemic heart disease as a risk factor.(27) Another study  from Norway(36) 
found increased prevalence of self-reported angina pectoris, hypertension and history of 
percutaneous coronary intervention but not for MI or CVA in patients with PsA, although  
cardiovascular risk factors were higher in these patients (higher prevalence of hypertension, 
tobacco smoking and increased BMI). This is in agreement with our findings which shows 
that traditional cardiovascular risk factors such as hypertension, diabetes, increased BMI 
and family history of ischaemic heart disease are more prevalent in patients with psoriasis 
and PsA as well as RA.  In our study, traditional cardiovascular risk factors fully account for 
MACE in PsA, suggesting adjustment in cardiovascular risk score is unnecessary for patients 
with PsA.  
Potential explanations for the discrepancies in findings surrounding cardiovascular risk may 
be associated with the differing methodologies employed. For instance, cross-sectional, 
case-control and cohort studies have investigated cardiovascular risk and the approach used 
may explain different results.  
Case definitions may also vary from study to study, for instance, previous studies using 
electronic health records have stratified patients using phototherapy and differing DMARDs 
as surrogate markers for disease severity which may not accurately classify the level of 
disease activity (25-27). Patients must assess the benefits and risks to starting treatments, in 
particular, systemic and biologic therapies which may cause adverse effects. Patient centred 
care and education means that an individual with psoriasis is informed to make a personal 
decision regarding their treatment and an absence of DMARD therapies in their patient 
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record may reflect this choice, rather than a proxy for disease severity. In fact, a great 
dissatisfaction has been reported with current psoriasis treatment options (37-39), which 
may cause resistance to agreeing to these medications.   
Previous studies have recruited patients attending secondary care while we studied patients 
in primary care, so we may have also included more patients with both milder and more 
severe disease, potentially representing individuals with the condition more appropriately. 
Cross-sectional studies conducted with patients recruited from secondary care, are more 
likely to include patients with increased comorbidities and severe diseases than patients 
considered in our study. This may be particularly important for PsA which is a 
heterogeneous condition. Disease varies from spondyloarthropathy, mono/oligo-arthritis or 
polyarthritis.   
The Swedish Early Psoriatic Arthritis Register found that ESR and CRP were higher in RA than 
PsA(40), which we have also found. Patients with polyarticular disease have higher ESR and 
CRP compared to patients with axial disease; whilst patients with mono-/oligo-arthritis have 
intermediate values. However, in psoriasis the ESR and CRP are usually normal and so not 
routinely assessed. In our study we also found no difference between controls and psoriasis.   
The fact that PsA patients had lower cardiovascular risk than patients with psoriasis is 
surprising given most patients with PsA suffer from psoriasis. This may be explained by 
higher usage of DMARDs, particularly methotrexate which can lower cardiovascular risk. 
However, in this study we found no interaction between DMARDs and PsA in terms of 
predicting cardiovascular risk. This differs from the study by Ogdie et al (27), who found an 
association between DMARD usage and higher cardiovascular risk in patients with psoriasis 
or PsA.  Ogdie et al used DMARD as a surrogate for disease severity. However, this is not 
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ideal as different DMARDs may have different impact on cardiovascular risk. For instance, 
Methotrexate is associated with reduced cardiovascular risk in patients with RA, while 
Acitretin is associated with hyperlipidaemia. Thus, difference in specific DMARDs used in 
psoriasis and PsA may contribute to why are results are not in agreement with Ogdie et al.  
Strength and Limitations 
Strengths 
A considerable strength of the study is the linkage between the GP and hospital admissions 
datasets, allowing the robust and reliable clinical picture of the population. This study also 
includes data on family history of ischaemic heart disease and ESR. MACE-related hospital 
admissions and associated deaths were identified using ICD-10 codes from hospital 
admissions, not relying on algorithms or text comments from health records and as such, 
MACEs are confirmed in the datasets. Utilising routine data we include a nation-wide, large-
scale population that does not result in a small, potentially unrepresentative sample (11, 24, 
41, 42) , restrict the sample to a single gender,  nor rely on self-reported diagnoses (43); 
linking routine health data means that a representative cohort can be created with 
conditions and events confirmed in one or all of the datasets. The routine data also allows 
more patients to be assessed, when compared to studies that use individuals who fulfil 
certain disease specific criteria, which may change or be updated in the future. Diagnostic 
criteria parameters for psoriatic arthritis and rheumatoid arthritis (44, 45) (there is no 
specific criteria for psoriasis, at present) may not be reliably available in routine data. 
Strictly adhering to criteria may cause early disease or less severe cases to be missed, even 
though the disease in these individuals could progress to meet all aspects of a given criteria 
over time. This would result in a limited and biased sample that is likely to have more severe 
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disease and therefore increased risk of comorbidities, including cardiac events, thereby 
over-inflating cardiac risk estimations. To utilise routine data to its full potential, it makes 
sense in this instance to allow clinical coding of conditions to define the populations, 
especially since primary care and secondary care physicians are qualified in identifying 
conditions, as our prevalence rates confirm;  our 0.71% rate of RA is comparable to the 1% 
cited elsewhere,(46) while our 0.2% rate of PsA is in line with general population estimates 
of 0.3% to 1%,(47) and finally, our 2.0% rate of psoriasis was similar to UK findings of 
1.9%.(48)  
Furthermore, the incidence rate of MI observed in our study was 1.9 per 1000 person (Table 
2) which is comparable to the rate of 1.5 reported for men and 0.6 reported for women 
living in England in 2010 (49) but our rate of stroke was 3.0 per 1000 person years, which is 
somewhat higher than the rates for men (1.8) and women (1.4) in England during 2007.(49)  
Limitations 
It is possible that there is some fluidity between the classified groups; as psoriasis and 
psoriatic arthritis frequently coexist, individuals who are assigned to the psoriasis group 
based on psoriasis Read Codes could actually have PsA which has not yet been detected. In 
addition, identifying individuals with arthropathy from GP records means that their 
condition may or may not be confirmed by a rheumatologist. It is worthy to note that our 
classification of PsA patients differs from those used previously. In this study, patients 
assigned to the PsA group could also have codes for psoriasis. The reason for this is that PsA 
and psoriasis frequently coexist and excluding individuals who present with both PsA and 
psoriasis codes from analysis could potentially omit 30% of the PsA population(50). 
Furthermore, another study has demonstrated that over a half of psoriasis patients who 
16 
 
received systemic or biologic therapies at study start had an inflammatory arthritis diagnosis 
by the end of follow-up (25).   
We can also expect a degree of missing data when using routine data for research purposes.    
We did not have a true marker for disease severity within the data and could not assess its 
role in cardiovascular risk in this study. However, as per previous studies we explored the 
role of DMARDs as a surrogate marker for severity and found no interaction between 
DMARDs and cardiovascular risk. 
There was limited data on the usage of biologic therapies however findings suggest that 
biologic usage is not associated with risk of MI in RA.  Further work to explore the role of the 
biologics will be useful to understand the true risk of cardiovascular disease in inflammatory 
arthritis and psoriasis.     
Conclusions 
Cardiovascular events were increased in female RA patients and in individuals with psoriasis 
after adjusting for traditional cardiovascular risk factors. The increased risk of cardiovascular 
events in RA may be attributed to inflammation. In psoriasis there are other additional 
unidentified risk factors for cardiovascular events and this needs more investigation. In PsA, 
risk of MACE appears to be attributed to increased prevalence of traditional cardiovascular 
risk factors. Cardiovascular risk score adjustment, such as recommended by EULAR for RA 
may not be applicable for PsA. Distinct factors are responsible for cardiovascular events in 
different chronic inflammatory diseases and as such cardiovascular risk reduction strategies 
need to be disease specific and not standard across these conditions.  
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Key messages 
 There is an increased cardiovascular risk in women with RA and men and women 
with psoriasis but not for PsA.  
 There are additional, unidentified risk factors of MACE in psoriasis.   
 Cardiovascular risk strategies need to be disease specific for inflammatory arthritis 
conditions and psoriasis.  
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Table 1: Baseline Characteristics 
 Control  
(n=1187706) 
RA 
(n=8650) 
PsA 
(n=2128) 
Psoriasis 
(n=24630) 
Age at study start 
(Confidence Intervals)  
 
Mean Age at 
diagnosis/ Random 
date  (SD) 
 
39.0 (16.3) 
(39 to 39) 
 
 
50 (17.2) 
(50 to 50) 
48.1 (15.0) 
(47.8 to 48.4) 
 
 
59.6 (14.6) 
(59.3 to 59.9) 
38.5 (13.2) 
(37.9 to 39.1) 
 
 
50.3 (13.1) 
(49.7 to 50.9) 
40.2 (15.4) 
(40 to 40.4) 
 
 
51.4 (16.2) 
(51.2 to 51.6) 
 
 
Male 49% 
(585049/1187422) 
(49.2 to 49.4)  
 
32% 
(2780/8650) 
(31.1 to 33.1) 
47% 
(998/2127) 
(44.8 to 49.1) 
49%  
(12037/24627) 
(48.3 to 50.0) 
Baseline BMI  25.5 (5.1) 
(25.5 to 25.5) 
 
 
26.8 (5.5) 
(26.7 to 26.9) 
27.8 (5.9) 
(27.5 to 28.1) 
26.5 (5.4) 
(26.4 to 26.6) 
Smoker 
 
21.2%  
(251423/1187706) 
(21.1 to 21.2) 
 
24.6%  
(2129/8650) 
(23.7 to 25.5) 
21.9% 
(467/2128) 
(20.2 to 23.8) 
27.9% 
(6877/24630) 
(27.4 to 28.5) 
Statin use 
 
0.8 % 
(9275/1187706) 
(0.8 to 0.8) 
1.6% 
(137/8650) 
(1.3 to 1.9) 
0.9% 
(19/2128) 
(0.6 to 1.4) 
1.1% 
(278/24630) 
(1.0 to 1.3) 
 
ESR (SD) 
 
8.5 (12.8) 
(8.5 to 8.5) 
 
11.0 (17.1) 
(10.6 to 11.4) 
 
12.1 (15.4) 
(11.4 to 12.8) 
 
8.9 (14.1) 
(8.7 to 9.1) 
     
ESR and Statin use were not included in the statistical model due to being on the MACE pathway. 
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Table 2: Smoking, comorbidity and medication history throughout patient record 
 Control  
(n=1187706) 
RA 
(n=8650) 
PsA 
(n=2128) 
Psoriasis 
(n=24630) 
Ever smoked 
 
(Confidence Intervals) 
50.9 % 
(604705/1187706) 
(50.8 to 51.0) 
50.1%  
(4410/8650) 
(50.2 to 52.0) 
46.7%  
(994/2128) 
(44.6 to 48.8) 
50%  
(12391/24630) 
(49.7 to 50.9) 
Hyperlipidemia 7.3% 
(86258/1187706) 
(7.2 to 7.3) 
 
13.9% 
(1202/8650) 
(13.2 to 14.6) 
12.6% 
(268/2128) 
(11.3 to 14.1) 
11.4% 
(2796/24630) 
(11.0 to 11.8) 
Diabetes  7.8%  
(92345/1187706) 
(7.7 to 7.8) 
 
14.1% 
(1220/8650) 
(13.4 to 14.9) 
13.1% 
(278/2128) 
(11.7 to 14.6) 
11.9% 
(2936/24630) 
(11.5 to 12.3) 
Hypertension 21.6% 
(256665/1187706) 
(21.5 to 21.7) 
 
39.7%  
(3434/8650) 
(38.7 to 40.7) 
33.3% 
(709/2128) 
(31.4 to 35.4) 
29.9% 
(7368/24630) 
(29.4 to 30.5) 
Ischaemic heart 
disease 
6.7%  
(79811/1187706) 
(6.7 to 6.8) 
 
14.5%  
(1258/8650) 
(13.8 to 15.3) 
7.8%  
(166/2128) 
(6.7 to 9.0) 
9.6% 
(2371/24630) 
(9.3 to 10.0) 
Family history of 
ischaemic heart 
disease 
14.1% 
(167577/1187706) 
(14.1 to 14.2) 
 
18.5% 
(1604/8650) 
(17.7 to 19.4) 
22.3% 
(474/2128) 
(20.6 to 24.1) 
18.5% 
(4562/24630) 
(18.0 to 19.0) 
NSAIDs 61.5% 
(730476/1187706) 
(61.4 to 61.6) 
 
92.9% 
(8034/8650) 
(92.3 to 93.4) 
92.6% 
(1970/2128) 
(91.4 to 93.6) 
79.9% 
(19680/24630) 
(79.4 to 80.4) 
DMARDs 1.2% 
(13735/1187706) 
(1.1 to 1.2) 
 
68.2% 
(5896/8560) 
(67.9 to 69.9) 
57.1% 
(1214/2128) 
(54.9 to 59.1) 
7.5% 
(1847/24630) 
(7.2 to 7.8) 
Oral steroids 13.5% 
(159918/1187706) 
(13.4 to 13.5) 
 
54.3% 
(4699/8650) 
(53.3 to 55.4) 
33.8% 
(720/2128) 
(31.9 to 35.9) 
22.6% 
(5566/24630) 
(22.1 to 23.1) 
Topical steroids 33.1% 
(393324/1187706) 
(33.0 to 33.2) 
53.8%  
(4656/8650) 
(52.8 to 54.9) 
80.3% 
(1708/2128) 
(78.5 to 81.9) 
84.4% 
(20778/24630) 
(83.9 to 84.8) 
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Table 3: Incidence of MI, Stroke and MACE (excluding individuals who have had events 
pre-diagnosis) 
 MI 
Cases 
Person 
Years 
Follow-
up 
Incidenc
e rate 
per 1000 
PY 
(95% CI) 
Strok
e 
Cases 
Person 
Years 
Follow-
up 
Incidenc
e rate 
per 1000 
PY 
(95% CI) 
MAC
E 
Cases 
Person 
Years 
Follow-
up 
Incidenc
e rate 
per 1000 
PY 
(95% CI) 
Control  
 
1370
8 
736712
4 
1.9 
(1.8 to 
1.9) 
2193
6 
737151
9 
3.0 
(2.9 to 
3.0) 
3345
6 
736712
4 
4.5 
(4.5 to 
4.6) 
 
RA 241 57005 4.2 
(3.7 to 
4.8) 
340 57093 5.4 
(5.4 to 
6.6) 
548 57005 9.6 
(8.8 to 
10.5) 
 
PsA 24 14801 1.6 
(1.1 to 
2.4) 
19 14801 1.3 
(0.8 to 
2.0) 
43 14801 2.9 
(2.2 to 
3.9) 
 
Psoriasi
s   
373 165063 2.3 
(2.0 to 
2.5) 
569 165200 3.4 
(3.2 to 
3.7) 
879 165063 5.3 
(5.0 to 
5.7) 
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Table 4: Hazard ratio of developing a major adverse cardiac event (MACE) by condition compared 
to control population with gender as an interaction term  
 Hazard Ratio 95% CI 
RA 1.0 0.8 to 1.3 
PsA 1.5 0.9 to 2.5 
Psoriasis* 1.2 1.0 to 1.4 
Interaction: 
RA x Female* 
1.3 1.0 to 1.7 
PsA x Female 0.5 0.2 to 1.1 
Psoriasis x Female 0.9 0.7 to 1.1 
Adjusted for:   
Female 0.7 0.6 to 0.7** 
Age at diagnosis 1.2 1.1 to 1.2** 
Age at study start 0.9 0.9 to 0.9** 
DMARD 1.1 1.0 to 1.3* 
NSAIDS 2.1 1.9 to 2.2** 
Topical steroids 0.9 0.9 to 0.9** 
Oral steroids 1.1 1.1 to 1.2** 
BMI 1.0 1.0 to 1.0  
Smoker 1.2 1.2 to 1.2** 
Hyperlipidemia 1.2 1.2 to 1.3** 
Diabetes 1.4 1.3 to 1.4** 
Hypertension 1.3 1.2 to 1.3** 
Ischaemic heart 
disease in family 
1.1 1.1 to 1.1** 
*p<0.05; **p<0.01  
 
  
26 
 
 
Table 5: Hazard ratio of developing a major adverse cardiac event (MACE) by condition compared 
to control population in individuals of 50 years old or younger  
 Hazard Ratio 95% CI 
RA 1.0 0.7 to 1.5 
PsA 1.2 0.6 to 2.3 
Psoriasis* 1.3 1.1 to 1.6 
Adjusted for:   
Female 0.5 0.5 to 0.5** 
Age at diagnosis 1.1 1.1 to 1.1** 
Age at study start 1.0 1.0 to 1.0* 
DMARD 1.2 1.0 to 1.6 
NSAIDS 2.1 1.9 to 2.5** 
Topical steroids 0.9 0.8 to 1.0* 
Oral steroids 1.2 1.1 to 1.3** 
BMI 1.0 1.0 to 1.0 
Smoker 1.5 1.3 to 1.6** 
Hyperlipidemia 1.3 1.1 to 1.4** 
Diabetes 1.6 1.4 to 1.8** 
Hypertension 1.4 1.3 to 1.6** 
Ischaemic heart 
disease in family 
1.1 1.0 to 1.2* 
*p<0.05; **p<0.01 
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